CNS-penetrant Bruton tyrosine kinase (BTK) inhibitors—a new class of medications capable of targeting both B cells and myeloid cells—are currently being evaluated in clinical trials for their potential use in MS. This evidence concerns the gene BTK and myeloid sarcoma.